University of Maryland Medical Center

Marlene and Stewart Greenebaum Comprehensive Cancer Center

Baltimore, MD

Sorting 5 by

Accepting patients

DREAMM13

A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more
  • Antibody Drug Conjugate (ADC)
  • BCMA
  • Phase 1

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Not yet accepting

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1

Accepting patients

P-BCMA-ALLO1

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)
Learn more
  • CAR T Cell (Allogeneic)
  • BCMA
  • Phase 1
  • Has results

Accepting patients

iMMAGINE-1

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2